Estimating the direct and indirect costs associated with Parkinson's disease
- PMID: 26511768
- DOI: 10.1586/14737167.2015.1103184
Estimating the direct and indirect costs associated with Parkinson's disease
Abstract
Parkinson's disease (PD) is a progressive, neurodegenerative disorder whose symptoms and manifestations greatly deteriorate the health, functional status and quality of life of patients, has severe consequences on their families and caregivers and supposes a challenge for the healthcare system and society. The aim of this paper is to comprehensively and descriptively review studies on the economic impact of the disease and interventions, analyzing major contributing factors to direct and indirect costs in PD. Cost-of-illness studies have shown that costs of PD are high, mainly due to drug, hospitalization and productivity loss, and tend to increase as the disease progresses. Studies on PD treatment have suggested that therapies for advanced PD (levodopa/carbidopa intestinal gel and apomorphine) and surgical procedures are cost-effective and cost saving, despite their high expenditures; however, further research such as on the economic impact of non-motor manifestations or on the cost-effectiveness of non-medical interventions is still needed.
Keywords: Parkinson’s disease; QALYs; cost of illness; cost–effectiveness; economic evaluation.
Similar articles
-
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.J Med Econ. 2015 Feb;18(2):155-65. doi: 10.3111/13696998.2014.979937. Epub 2014 Nov 11. J Med Econ. 2015. PMID: 25348011
-
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.Clin Drug Investig. 2010;30(11):789-98. doi: 10.2165/11538520-000000000-00000. Clin Drug Investig. 2010. PMID: 20818839
-
Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.World Neurosurg. 2016 Sep;93:44-9. doi: 10.1016/j.wneu.2016.05.028. Epub 2016 May 20. World Neurosurg. 2016. PMID: 27216925 Review.
-
Costs of drug treatment in Parkinson's disease.Mov Disord. 1998 Mar;13(2):249-54. doi: 10.1002/mds.870130209. Mov Disord. 1998. PMID: 9539337
-
Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.Pharmacoeconomics. 2001;19(10):1013-38. doi: 10.2165/00019053-200119100-00004. Pharmacoeconomics. 2001. PMID: 11735671 Review.
Cited by
-
Neuroimaging and serum biomarkers of neurodegeneration and neuroplasticity in Parkinson's disease patients treated by intermittent theta-burst stimulation over the bilateral primary motor area: a randomized, double-blind, sham-controlled, crossover trial study.Front Aging Neurosci. 2023 Oct 5;15:1258315. doi: 10.3389/fnagi.2023.1258315. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37869372 Free PMC article.
-
Towards improved access to device-aided therapies in advanced PD: the importance of cooperation of different disciplines.J Neural Transm (Vienna). 2023 Nov;130(11):1433-1441. doi: 10.1007/s00702-023-02664-z. Epub 2023 Jul 13. J Neural Transm (Vienna). 2023. PMID: 37439943 Review.
-
Could exercise hormone irisin be a therapeutic agent against Parkinson's and other neurodegenerative diseases?Metabol Open. 2023 Jan 31;17:100233. doi: 10.1016/j.metop.2023.100233. eCollection 2023 Mar. Metabol Open. 2023. PMID: 36785617 Free PMC article.
-
Association of 7-Day Profiles of Motor Activity in Marital Dyads with One Component Affected by Parkinson's Disease.Sensors (Basel). 2023 Jan 17;23(3):1087. doi: 10.3390/s23031087. Sensors (Basel). 2023. PMID: 36772127 Free PMC article.
-
Understanding support systems for Parkinson's disease management in community settings: A cross-national qualitative study.Health Expect. 2023 Apr;26(2):670-682. doi: 10.1111/hex.13691. Epub 2022 Dec 27. Health Expect. 2023. PMID: 36573594 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
